Implantica submits final response to FDA in the PMA application for RefluxStop® for U.S. market approval

Contributed by: PR Newswire

Tags

IMPLANTICA-FDA

More Like This

Implantica announces U.S. FDA has provided feedback on the final RefluxStop® PMA submission, Module 3

Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval

Implantica announces continuing progress in modular PMA application to FDA for RefluxStop™

Implantica submits FDA PMA application Clinical Module 2 for RefluxStop™ for U.S. market approval

Implantica submits U.S. FDA Premarket Approval (PMA) application for RefluxStop® (first module)

Implantica announces positive feedback received from U.S. FDA of the RefluxStop™ PMA Module 2 submission

Implantica announces Module 1 is accepted and closed by FDA in the PMA application for RefluxStop™

Implantica announces finalization of remarkable 5-year pivotal CE mark study results and gears up for the Module 2 submission of PMA application to FDA for RefluxStop™